Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The 1-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk over the past year. As of today (2026-09-22), Aytu BioPharma's 1-Year Sharpe Ratio is -79.68.
Aytu BioPharma (LTS:0A8M) 1-Year Sharpe Ratio Explanation
The 1-Year Sharpe Ratio inidicates the risk-adjusted return of an investment over the past year. It is calculated as the annualized result of the average monthly excess return divided by its standard deviation over the past year. The monthly excess return is the monthly investment return minus the monthly risk-free rate (typically the 10-year Treasury Constant Maturity Rate). If the risk-free rate for a specific region is not available, U.S. data is used by default.
The greater a portfolio's Sharpe Ratio, the better its risk-adjusted performance. A negative Sharpe Ratio means the risk-free rate is greater than the portfolio’s historical or projected return, or else the portfolio's return is expected to be negative.
Aytu BioPharma 1-Year Sharpe Ratio Related Terms
LTS:0A8M vs BFRI, TXMD, ETST: 1-Year Sharpe Ratio Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Aytu BioPharma's 1-Year Sharpe Ratio, along with its competitors' market caps and 1-Year Sharpe Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aytu BioPharma 1-Year Sharpe Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Aytu BioPharma's 1-Year Sharpe Ratio distribution charts can be found below:
* The bar in red indicates where Aytu BioPharma's 1-Year Sharpe Ratio falls into.
The 1-Year Sharpe Ratio measures the performance of an investment such as a stock or portfolio compared to a risk-free asset. A stock / portfolio's 1-Year Sharpe Ratio can be calculated by dividing the difference between the one-year returns of the investment and the risk-free rate, by the standard deviation of the investment returns over one year.
Aytu BioPharma (LTS:0A8M) has a 1-Year Sharpe Ratio of -79.68 as of Sep. 22, 2026. 1-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk. View historical data for Aytu BioPharma and its competitors.
Is Aytu BioPharma's 1-Year Sharpe Ratio too high?
Aytu BioPharma's current 1-Year Sharpe Ratio is -79.68. Overall, Aytu BioPharma has a GF Score™ of 42/100, reflecting its overall financial health beyond just this single metric.
How does Aytu BioPharma's 1-Year Sharpe Ratio compare to BFRI and TXMD?
Aytu BioPharma's 1-Year Sharpe Ratio of -79.68 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 1-Year Sharpe Ratio for a Drug Manufacturers company?
A good 1-Year Sharpe Ratio depends on the Drug Manufacturers industry context. However, 1-Year Sharpe Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 1-Year Sharpe Ratio mean?
A high 1-Year Sharpe Ratio can signal that a stock is expensive relative to its fundamentals. 1-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk. View historical data for Aytu BioPharma and its competitors. Aytu BioPharma's current 1-Year Sharpe Ratio is -79.68. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aytu BioPharma stock overvalued right now?
Aytu BioPharma (LTS:0A8M) has a current 1-Year Sharpe Ratio of -79.68. The stock's GF Value™ is $0.98, compared to a current price of $2.20 — trading 124.5% above its estimated fair value. The current 1-Year Sharpe Ratio is -79.68. Aytu BioPharma's overall GF Score™ is 42/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 1-Year Sharpe Ratio calculated?
1-Year Sharpe Ratio is calculated from a company's financial statements. For Aytu BioPharma (LTS:0A8M), the current 1-Year Sharpe Ratio is -79.68 as of Sep. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Aytu BioPharma (LTS:0A8M) Overvalued in 2026?
Based on GuruFocus' analysis, Aytu BioPharma stock appears to be overvalued.
The current stock price of $2.20 is trading 124.5% above its estimated GF Value™ of $0.98.
Key valuation signals for LTS:0A8M:
1-Year Sharpe Ratio: -79.68
GF Value™: $0.98 vs. price of $2.20 (124.5% above fair value)
No single metric tells the full story. See the LTS:0A8M stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Aytu BioPharma Inc. is a commercial-stage specialty pharmaceutical company focused on prescription therapeutics for pediatric and related conditions. Its core business centers on ADHD treatments, including Adzenys XR-ODT, Cotempla XR-ODT, and generic methylphenidate products, along with other prescription medicines such as Karbinal ER for allergies and Poly-Vi-Flor and Tri-Vi-Flor for pediatric vitamin and fluoride supplementation. The company also markets consumer health products. Aytu sells primarily in the United States through pharmaceutical wholesalers, pharmacies, and third-party distribution partners, generating revenue from product sales. It has pursued development programs for rare diseases, including AR101 (enzastaurin) for vascular Ehlers-Danlos Syndrome, though its operations are mainly driven by its commercial prescription portfolio. The company operates as a single reportable business segment.
42GF Score
Get the complete analysis for LTS:0A8M
1-Year Sharpe Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0A8M has been successfully added to your 
